Log in to search using one of your social media accounts:

 

Brainstorm adds UCal Irvine Medical Center to late-stage NurOwn trial

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it inked an agreement with the University of California Irvine Medical Center to enroll patients in the Phase III trial of its NurOwn mesenchymal stem cell-based platform for amyotrophic lateral sclerosis. This marks the third medical center to work with Brainstorm to enroll patients in the late-stage pivotal trial. The company said last week that Massachusetts General Hospital and California Pacific Medical Center both agreed to participate in the trial. Get the full story at our sister site, Drug Delivery Business News. The post Brainstorm adds UCal Irvine Medical Center to late-stage NurOwn trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Regenerative Medicine Stem Cells Wall Street Beat BrainStorm Cell Therapeutics Inc. Source Type: news

Related Links:

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that the first patients have been enrolled in its Phase III trial evaluating NurOwn as a treatment for amyotrophic lateral sclerosis, or ALS, at Massachusetts General Hospital and UC Irvine Medical Center. The trial, which is slated to enroll 200 patients, is designed to include the pre-specified patient subgroups who saw superior outcomes in the NurOwn Phase II ALS trial. BrainStorm said it expects top-line data from the trial in 2019. Get the full story at our sister site, Drug Delivery Business News. The post BrainStorm enrolls first ALS patient in late-stage NurO...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neurological Stem Cells Wall Street Beat BrainStorm Cell Therapeutics Inc. Source Type: news
Trial supported by a $16M non-dilutive grant from CIRM Top-line data are expected in 2019 HACKENSACK, N.J. and PETACH TIKVA, Israel, Oct. 16, 2017 -- (Healthcare Sales &Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today an... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
TEL AVIV (Reuters) - BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
We report the transcriptome analysis of human purified motoneurons, obtained from FUS wild-type or mutant isogenic induced pluripotent stem cells (iPSCs). Gene ontology analysis of differentially expressed genes identified significant enrichment of pathways previously associated to sporadic ALS and other neurological diseases. Several microRNAs (miRNAs) were also deregulated in FUS mutant motoneurons, including miR-375, involved in motoneuron survival. We report that relevant targets of miR-375, including the neural RNA-binding protein ELAVL4 and apoptotic factors, are aberrantly increased in FUS mutant motoneurons. Charac...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
Publication date: 3 October 2017 Source:Cell Reports, Volume 21, Issue 1 Author(s): Alyssa N. Coyne, Ileana Lorenzini, Ching-Chieh Chou, Meaghan Torvund, Robert S. Rogers, Alexander Starr, Benjamin L. Zaepfel, Jennifer Levy, Jeffrey Johannesmeyer, Jacob C. Schwartz, Hiroshi Nishimune, Konrad Zinsmaier, Wilfried Rossoll, Rita Sattler, Daniela C. Zarnescu Amyotrophic lateral sclerosis (ALS) is a synaptopathy accompanied by the presence of cytoplasmic aggregates containing TDP-43, an RNA-binding protein linked to ∼97% of ALS cases. Using a Drosophila model of ALS, we show that TDP-43 overexpression (OE) in motor neurons ...
Source: Cell Reports - Category: Cytology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Original Article Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: REVIEW ARTICLE Source Type: research
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Contributors : Giulia E Tyzack ; Claire E Hall ; Christopher R Sibley ; Rickie Patani ; Andras LakatosSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAstrocyte   responses to neuronal injury may be beneficial or detrimental to neuronal recovery, but the mechanism that determines these different responses are poorly understood. Transcriptional analysis showed that EphB1 induces a protective inflammatory signature in astrocytes, which is distinct from the r esponse evoked by interleukin (IL)-6, which is known to have both pro- and anti-inflammatory properties. We demonstrate that t...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
More News: ALS | Clinical Trials | Hospitals | Stem Cell Therapy | Stem Cells